The growth inhibitory effects of six guanine and guanosine analogs, 3-deazaguanine (compound 1); 3-deazaguanosine (compound 2); 6-aminoallopurinol (compound 3); 9-I-xylofuranosyl guanine (compound 4); a ribosylated derivative of compound 3, 6-aminopyrazolo(3,4-d)pyrimidin-4-one (compound 5); and 5-aminoformycin B (compound 6), were tested against some pathogenic members of the family of American Trypanosomatidae. Compounds 1 and 2 were highly active against Trypanosoma cruzi, Trypanosoma rangeli, and American Leishmania spp. in in vitro culture forms. Both compounds also showed antiprotozoal activity in T. cruzi-infected mice, with the optimal dose being about 30 mg/kg of body weight per day given as 10 consecutive doses. Compound 3 was the most active compound in vitro, inhibiting all of the American Trypanosomatidae culture forms tested. It was also highly inhibitory in mice that were acutely infected with T. cruzi, with the optimal dose being about 10 mg/kg of body weight per day. Ribosylation of compound 3 resulted in a derivative that showed decreased inhibitory activity on Trypanosomatidae multiplication. Compound 6 was highly inhibitory of in vitro multiplication of American Leishmania and T. rangeli but had no effect on T. cruzi epimastigotes and on mice that were acutely infected with T. cruzi. Compound 4 showed only a slight effect on T. cruzi epimastigotes.
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Recent reviews on the chemotherapy of Chagas' disease and American cutaneous leishmaniasis have emphasized the deficiencies of currently available therapeutic agents and the need for new ones (1, 31) . These diseases are still important health problems in the Western Hemisphere, while Trypanosoma rangeli, which is apparently a harmless parasite of humans and a variety of birds and domestic animals, infects about 52% of exposed people in endemic areas (23) .
With regard to purine metabolism, with the exception of adenine, the incorporation of purine bases by Trypanosoma cruzi is similar to that of Leishmania spp. (11) . Because purine bases are incorporated more readily than their respective ribonucleosides, it appears that the major biosynthetic pathway from a purine base to its ribonucleoside is direct, via purine phosphoribosyltransferases, rather than a sequential conversion from base to ribonucleoside to ribonucleotide (11) . In contrast to Leishmania spp. (19, 22) and African trypanosomes (15) , which have very high nucleosidecleaving activities, purine ribonucleosides are remarkably stable in T. cruzi (11) .
With regard to guanine metabolism in members of the family Trypanosomatidae, data are consistent with a direct conversion of guanine to GMP which could be converted sequentially to IMP and AMP by GMP reductase (EC 1.6.6.8) and the adenylosuccinate synthetase (EC 6.3.4.4) to GTP. For guanosine analogs to reach the nucleotide stage, they must be modified by purine nucleoside-cleaving enzymes, which have been demonstrated in several Trypanosomatidae (16, 21, 24) , to produce the parent heterocyclic compound, which then acts as a substrate for hypoxanthine phosphoribosyltransferase (HPRT; EC 2.4.2.8), resulting in the 5'-phosphate derivative by condensation of the heterocycle with phosphoribosyl pyrophosphate.
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Inhibition of guanosine nucleotide utilization may be important for antileishmanial activity because mycophenolic acid, an inhibitor of GMP synthesis from IMP, inhibits amastigote multiplication in vitro (13) .
Certain hypoxanthine (17, 30) , adenine (6, 8, 9) , and inosine (18, 20) analogs are biologically active against Leishmania spp., T. cruzi, and T. rangeli (10) culture forms. Because purines reverse the inhibitory activity of these analogs (8, 17, 18) , we examined the biological activity of certain guanine and guanosine analogs on the multiplication of culture forms of Leishmania and Trypanosoma (promastigotes and epimastigotes, respectively) and of mammalian forms of T. cruzi.
Guanine and guanosine analogs have been studied for any inhibitory activity on Leishmania tropica (12) and T. cruzi (25) . Using several of these analogs (Fig. 1) , we investigated modifications of the purine structure to determnine which features of the molecules are important for activity against American Leishmania and Trypanosoma spp. We found that these analogs are potent inhibitors of the growth of American Trypanosomatidae in culture, some of which are also highly active in T. cruzi-infected mice.
MATERIALS AND METHODS
Parasites. The Ma, OPS-86, ES, Fl, and Ya strains of T. cruzi were obtained from the blood of human patients (4, 7) . Some of their biological characteristics have been described previously (4, 5) . Except for strain Ya, which was classified as belonging to zymodeme type 2, all other isolates were included in zymodeme type 1. They were maintained as epimastigotes in culture (7) or as trypomastigotes by serial syringe passages of infected blood in NMRI mice (2) . During mouse-to-mouse passages no variation in virulence was detected when compared with the virulence of the same cryopreserved strains.
Leishmania mexicana LR, MP, and AZV and Leishmania ANTIMICROB. AGENTS CHEMOTHER. Trypanosoma rangeli San Juan de los Morros was obtained from Felix Pifano, as described previously (3).
Culture methods. T. cruzi epimastigotes and American Leishmania spp. promastigotes were grown at 28°C in a semidefined fetal calf serum-containing medium (7) . Its initial purine concentration was identical to that used in our drug inhibitory tests with American Leishmania spp. (9) and T. cruzi (J. L. Avila, M. A. Polegre, and R. K. Robins, Comp. Biochem. Physiol., in press). T. rangeli was grown at 28°C in a purine-depleted liver infusion-tryptose medium. After dialysis the concentration of total purines or pyrimidines in the culture medium was lower than 0.1 ,g/ml, as determined by high-performance liquid chromatography (10) .
Parasites were cultured in 30-ml plastic tissue culture flasks (Fisher Scientific Co., Springfield, N.J.) with an inoculum of 0.5 x 106 cells per ml. Culture medium components were obtained from GIBCO Laboratories, Grand Island, N.Y. Nucleotides, nucleosides, glucose, and hemin were purchased fromn Sigma Chemical Co., St. Louis, Mo.
Source of compounds. The six guanine or guanosine analogs evaluated for antiprotozoal activity were synthesized as described elsewhere (14, 26) . Formycin B and 4-aminopyrazolo(3,4-d)pyrimidine (APP) were obtained as described previously (6, 9) .
In vitro studies. Pure drugs were prepared in 1 N NaOH and then added aseptically to culture medium at day 0, taking care to adjust the pH with a few drops of 1 N HCI to about pH 6.4 (T. cruzi) or pH 7.0 (Leishmania spp. and T. rangeli). Under these experimental conditions solubilization of the analogs studied in culture medium was complete up to 25 ,ug/ml. Every 2 days parasites were counted in a hemacytometer (7), and the counts were compared with those of controls grown in absence of drug. The 50% inhibitory dose (ID50), the drug concentration that caused a 50% reduction in growth compared with that in untreated control cultures, was determined from plots of cell growth versus drug concentration.
In vivo studies. NMRI mice were inoculated by the intraperitoneal route with 104 to 106 T. cruzi bloodstream isolates. For these mice the lethal dose of each of the T. cruzi strains was approximately 105 organisms. Intraperitoneal treatment was initiated the day after inoculation. Mortality was recorded daily, and the median survival time (MST) was determined. The minimal therapeutic dose (MTD) was the lower dose that produced a significant increase in MST in treated animals when compared with that in untreated infected mice. cruzi, and T. rangeli culture forms (Fig. 2) ; their ID50s varied widely (Table 1 ). 9-P-Xylofuranosyl guanine (compound 4) was weakly inhibitory only for T. cruzi epimastigotes, while compound 3 was highly inhibitory for the multiplication ofall three Trypanosomatidae culture forms (Fig. 2 and Table 1 ). Compound 3 was the most active of the six compounds tested in vitro. Compound 5 showed decreased inhibitory activity on American Trypanosomatidae culture forms. Finally, 5-aminoformycin B (compound 6) was highly inhibitory only for American Leishmania and T. rangeli mttltiplication. This compound showed no inhibitory activity against multiplication of the T. cruzi culture form, up to a concentration of 25 ,ug/ml.
RESULTS

In vitro effects on
For comparative purposes, results obtained in the presence of Formycin B and APP in the culture medium also are presented in Table 1 . Both drugs were highly inhibitory of all three Trypanosomatidae culture forms. The ID50 for APP on T. rangeli and Leishmania was similar to that found for compound 3 . Formycin B displayed a lower ID50 than compound 3 Trypanosoma spp. were more sensitive to compound 3 than to Formycin B.
The inhibitory effect of the guanine and guanosine analogs was cytostatic in all cases, because when they were subcultured in drug-free medium, parasites resumed their normal growth rates, reaching control cellular growth in a 4-day periQd (data not shown). No change in sensitivity pattern toward a given drug was detected when epimastigotes that were maintained serially in culture were compared with same parasites that were kept cryopreserved for 4 years and allowed to grow again under similar culture conditions.
In vivo effects on T. cruzi-infected mice. Experiments to determine the in vivo effects on T. cruzi-infected mice were carried out in a concentration range of 5 to 40 mg/kg of body weight per day and were administered twice a day as 10 consecutive doses (Table 2) . No apparent signs of drug toxicity, such as gross weight loss, diarrhea, or hair loss, a The results are the mean MST in groups of 10 mice. The MST of untreated and infected mice was 12 days. Doses were given for 10 consecutive days and were given by the intraperitoneal route.
were observed in any of the experiments at the end of treatment at therapeutic dosages. With an inoculum size between io3 and 106, all untreated control mice inoculated with the blood form trypomastigotes of T. cruzi Ya died within 18 days of challenge. The MST was 12 days. The in vivo activities of the analogs differed from those in vitro. The only active analogs in vivo were compounds 1 to 3, as demonstrated by a significantly increased MST. Survivors of inoculation with strain Ya were not cured, because subinoculations to susceptible control mice revealed the presence of parasites 70 days after the completion of treatment. Average parasitemias in mice treated with 30 mg of active drug per kg per day were about 1 to 2% of controls for mice treated with compounds 1 to 3 (P < 0.001) at 15 days postinoculation. The MTD was about 30 mg/kg for compounds 1 and 2 and 10 mne/kg for compound 3.
DISCUSSION
The observations reported here suggest that guanine and guanosine analogs provide good models for the design of agents with antiprotozoal activity. Of the six different analogs tested, compounds 1, 2, and 3 were the most promising, as they strongly inhibited multiplication of culture forms of three members of the Trypanosomatidae family and showed activity in T. cruzi-infected mice.
Comipound 3 was, on a molar basis, the most active against T. cruzi culture forms and in T. cruzi-infected mice.
It inhibited mnultiplication of all three American Trypanosomatidae culture forms in the concentration range of 7 to 13 ptM, while compound 6 highly inhibited T. rangeli but not T. Avila et al., in press) ( Table 1) .
Berman et al. (12) found that compounds 1 and 2 are active in vitro on L. tropica amastigotes (ID50, 40 and 1 ,ug/ml, respectively); those ID50s are different from those reported in this report as being effective against American Leishmania promastigotes. The disparity perhaps can be explained by the different Leishmania species and evolutive forms studied.
With regard to in vivo activity, MTDs found for compounds 1 and 2 were similar to those reported for 4-hydroxypyrazolo(3,4-d)pyrimidine (HPP)-treated T. cruziinfected mice (2) but about 60-fold higher than that reported for APP (6) . On the other hand, the MTD of compound 3 is 3-fold lower but 20-fold higher than those found for HPP (5) and APP (1), respectively, being 4-fold higher than that reported as optimal in the case of Formycin B (20; Avila et al., in press). The MTDs of compounds 1 and 2 that are useful for treating acutely chagasic mice are about 5-fold lower than the dosage tolerated by tumor-treated mice (14) , while for compound 3, the MTD was about 40-fold lower than the 50% lethal dose (29) .
In a previous study (25) , 8-azaguanine lacked protective effects in T. cruzi-infected mice. The difference between those and the present results might be explained by differences in the chemical structures of the guanine analogs that were tested.
Compounds 3 and 5 are members of the pyrazolo(3,4-d)pyrimidine family. In American Trypanosomatidae, HPP is converted to HPP ribonucleoside-5'-phosphate by an unique enzyme, nucleoside phosphoribosyltransferase, of the parasite. Selective amination of HPP ribonucleoside-5'-phosphate by adenylosuccinate synthetase and succino-AMP lyase produces APP nucleoside-5'-phosphate, which is then incorporated into RNA of the parasite as the 5'-triphosphate, resulting in cytotoxicity to the parasite (17) . It must be emphasized, however, that striking differences have been found for the effect of pyrazolopyrimidines on culture and blood forms of T. cruzi. Drug insensitivity for most of the pyrazolopyrimidine derivatives that have been tested is trypomastigote specific (Avila et al., in press ). This fact could explain, for example, the observed variations in analog activities in vitro and in vivo reported here.
The mechanism of action of compound 3 and its ribonucleoside on pathogenic American Trypanosomatidae is still unknown. They could be metabolized as other allopurinol derivatives or as guanine analogs. In the latter case it is noteworthy that inhibition of guanosine nucleotide utilization may be important for antileishmanial activity (13) .
It is relevant to note that Streeter and Koyama (28) have evaluated the inhibitory effects of compounds 1 and 2 on purine nucleotide biosynthesis in Ehrlich ascites tumor cells and found that the enzymes most affected were HPRT and IMP dehydrogenase. These investigators proposed that compound 2 is converted to compound 1 and then phosphoribosylated to 3-deazaguanylic acid. These results have been confirmed by using rat erythrocytes and L-1210 leukemia cells, and a fairly close correlation was found between the in vivo and in vitro data (29) .
In sensitive Trypanosomatidae the metabolic targets of compounds 1 and 2 are unknown. If compound 2 is metabolized in Trypanosomatidae, as in Ehrlich ascites tumor cells, however, HPRT or IMP dehydrogenase could be inhibited. Another possible target in guanine metabolism is GMP reductase, which is strongly inhibited in Leishmania donovani by IMP analogs (27) .
Because there were no apparent signs of drug toxicity in our experiments, and although our data show that trdatment of mice with guanine and guanosine analogs does not result in parasitological cure of the animals after short treatment, the fact that some of the drugs were able to markedly reduce parasitemia and completely suppress death during acute infection indicates that there is a need for continued studies in this area.
